Impact of molecular profiling on overall survival of patients with advanced ovarian cancer

open access
 

Impact of molecular profiling on overall survival of patients with advanced ovarian cancer

PDF |  HTML
 

DOI: 10.18632/oncotarget.7835

Thomas J. Herzog1,*, David Spetzler2, Nick Xiao2, Ken Burnett2, Todd Maney2, Andreas Voss2, Sandeep Reddy2, Robert Burger3, Thomas Krivak4, Matthew Powell5, Michael Friedlander6, William McGuire7

1 University of Cincinnati Cancer Institute, Cincinnati, OH, USA

2 Caris Life Sciences, Phoenix, AZ, USA

3 University of Pennsylvania, Philadelphia, PA, USA

4 Western Pennsylvania Gynecological Oncology, Mars, PA, USA

5 Washington University School of Medicine, St. Louis, MO, USA

6 Prince of Wales Hospital, Sydney, Australia,

7 VCU Massey Cancer Center, Richmond, VA, USA

Published: March 01, 2016

 

                        Patient characteristics

There were 241 EOC patients with advanced stage cancers who underwent treatment and had at least 9 months of follow-up data, diagnostic staging of at least IIIC or having metastasis or treatments prior to profiling. Of 241 eligible patients, 17 were excluded because they received no drugs after the time of tissue collection or the drugs they received were not classified by the molecular profile (received no drugs of predicted benefit or lack-of-benefit; Figure 1).

In conclusion, this report suggests a potential predictive role of molecular profiling to avoid use of inactive therapies. Additionally, a prognostic biomarker-derived phenotype was identified that demonstrated particularly inferior OS. The conclusions generated here, while intriguing, will need to be validated in an additional prospective observational study with much larger patient numbers.